ÌÇÐÄvlog

[Skip to Navigation]
Sign In

October 2024 - April 2015

Decade

Year

Issue

October 2023, Vol 9, No. 10, Pages 1321-1467

Original Investigation

Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non–Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2023;9(10):1348-1355. doi:10.1001/jamaoncol.2023.2751

This randomized clinical trial assesses the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy vs chemotherapy alone for patients with resectable stage IIIA or IIIB non–small cell lung cancer (NSCLC).

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2023;9(10):1356-1363. doi:10.1001/jamaoncol.2023.2761

This randomized clinical trial compares the efficacy and safety of avelumab as a second-line treatment in patients with deficient mismatch repair and/or microsatellite instability (dMMR/MSI) metastatic colorectal cancer (mCRC) who had not been treated previously with immunotherapeutic agents and in whom standard first-line treatment failed with standard second-line treatment.

A Geospatial Analysis of Disparities in Access to Oncofertility Services

Abstract Full Text
free access has audio
JAMA Oncol. 2023;9(10):1364-1370. doi:10.1001/jamaoncol.2023.2780

This cross-sectional study characterizes the distribution of centers offering fertility preservation services in the US and quantifies the number of self-identified reproductive-age female individuals living outside of geographically accessible areas.

Medicaid Expansion of the Patient Protection and Affordable Care Act and Participation of Patients With Medicaid in Cancer Clinical Trials

Abstract Full Text
free access
JAMA Oncol. 2023;9(10):1371-1379. doi:10.1001/jamaoncol.2023.2800

This cohort study assesses participation of patients with Medicaid in cancer clinical trials after Patient Protection and Affordable Care Act Medicaid expansion.

Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2023;9(10):1381-1389. doi:10.1001/jamaoncol.2023.2909

This secondary analysis of a randomized clinical trial assesses whether trastuzumab plus pertuzumab without chemotherapy is an optimal first-line treatment in patients with metastatic breast cancer.

Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19

Abstract Full Text
open access
JAMA Oncol. 2023;9(10):1390-1400. doi:10.1001/jamaoncol.2023.2934

This cohort study assesses the association between anticancer therapy exposure and thromboembolic events following COVID-19 diagnosis in patients with cancer.

The Global, Regional, and National Burden of Adult Lip, Oral, and Pharyngeal Cancer in 204 Countries and Territories: A Systematic Analysis for the Global Burden of Disease Study 2019

Abstract Full Text
open access
JAMA Oncol. 2023;9(10):1401-1416. doi:10.1001/jamaoncol.2023.2960

This systematic analysis assesses the total and risk-attributable burden of lip and oral cavity cancer and other pharyngeal cancer for 204 countries and territories and by Socio-demographic Index using 2019 Global Burden of Diseases, Injuries, and Risk Factors Study estimates.

Deaths Due to COVID-19 in Patients With Cancer During Different Waves of the Pandemic in the US

Abstract Full Text
free access
JAMA Oncol. 2023;9(10):1417-1422. doi:10.1001/jamaoncol.2023.3066

This cross-sectional study examines COVID-19 mortality in patients with cancer compared with the general population during different waves of the pandemic.

Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Abstract Full Text
open access
JAMA Oncol. 2023;9(10):1423-1431. doi:10.1001/jamaoncol.2023.3284

This systematic review and meta-analysis evaluates the efficacy and safety of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma with Child-Pugh class B liver function.

Brief Report

Association of Reducing the Recommended Colorectal Cancer Screening Age With Cancer Incidence, Mortality, and Costs in Canada Using OncoSim

Abstract Full Text
open access
JAMA Oncol. 2023;9(10):1432-1436. doi:10.1001/jamaoncol.2023.2312

This economic evaluation computational study uses microsimulation modeling to estimate the association of a lowered initiation age for colorectal cancer screening by biennial fecal immunochemical test with colorectal cancer incidence, mortality, and health care system costs in Canada.

Assessment of Artificial Intelligence Chatbot Responses to Top Searched Queries About Cancer

Abstract Full Text
free access
JAMA Oncol. 2023;9(10):1437-1440. doi:10.1001/jamaoncol.2023.2947

This cross-sectional study assesses the accuracy, understandability, and actionability of responses generated by 4 artificial intelligence chatbots to the most common search queries about the 5 most common cancers.

Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis

Abstract Full Text
open access
JAMA Oncol. 2023;9(10):1441-1446. doi:10.1001/jamaoncol.2023.3295

This meta-analysis investigates the efficacy and safety of nivolumab plus ipilimumab vs nivolumab alone in the treatment of advanced cancers other than melanoma.

Research Letter

Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma: A Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2023;9(10):1457-1459. doi:10.1001/jamaoncol.2023.2789

This randomized clinical trial presents the final 5-year follow-up results of neoadjuvant talimogene laherparepvec (T-VEC) plus surgery in patients with advanced melanoma.

Use of Artificial Intelligence Chatbots for Cancer Treatment Information

Abstract Full Text
open access
JAMA Oncol. 2023;9(10):1459-1462. doi:10.1001/jamaoncol.2023.2954

This survey study examines the performance of a large language model chatbot in providing cancer treatment recommendations that are concordant with National Comprehensive Cancer Network guidelines.

Review

Immunotherapy in the Treatment of Localized Genitourinary Cancers

Abstract Full Text
has active quiz
JAMA Oncol. 2023;9(10):1447-1454. doi:10.1001/jamaoncol.2023.2174

This systematic review examines the use of immunotherapy in the management of localized genitourinary cancers.

JAMA Oncology Clinical Challenge

Oral Mucosal Pigmentation in a Patient With Mycosis Fungoides

Abstract Full Text
has active quiz
JAMA Oncol. 2023;9(10):1455-1456. doi:10.1001/jamaoncol.2023.2797

A 53-year-old woman with mycosis fungoides presented with hyperpigmentation of the oral mucosa. Examination of the mouth revealed multiple coalescing painless nonpruritic black macules and patches on the tongue, roof of the mouth, and buccal mucosa. What is your diagnosis?

Viewpoint

Addressing the Need for Diversity in Scalp Cooling Trials

Abstract Full Text
JAMA Oncol. 2023;9(10):1331-1332. doi:10.1001/jamaoncol.2023.2906

This Viewpoint emphasizes the importance of diverse representation in research on scalp cooling to avoid hair loss during chemotherapy.

From Bragg Peaks to Adaptive Fields—The Need for Evidence-Based Adoption of New Technologies in Radiotherapy

Abstract Full Text
JAMA Oncol. 2023;9(10):1333-1334. doi:10.1001/jamaoncol.2023.2931

This Viewpoint discusses the need for multi-institutional prospective randomized trials of new technologies in radiotherapy to improve the therapeutic ratio and safety of radiotherapy treatments.

Miscommunication in Cancer Care—Do You Hear What I Hear?

Abstract Full Text
JAMA Oncol. 2023;9(10):1335-1336. doi:10.1001/jamaoncol.2023.2944

This Viewpoint identifies examples of bad communication from cancer clinicians toward patients as well as better methods for clinicians to use when communicating with patients with cancer.

Editorial

Artificial Intelligence—From Starting Pilots to Scalable Privilege

Abstract Full Text
free access
JAMA Oncol. 2023;9(10):1341-1342. doi:10.1001/jamaoncol.2023.2867

ÌÇÐÄvlog Call for Papers on Health and the 2024 US Election

Abstract Full Text
free access
JAMA Oncol. 2023;9(10):1343-1344. doi:10.1001/jamaoncol.2023.3619

Reducing the Risks of Nuclear War—The Role of Health Professionals

Abstract Full Text
free access
JAMA Oncol. 2023;9(10):1345-1346. doi:10.1001/jamaoncol.2023.3622
Invited Commentary

Medicaid Expansion and Clinical Trials—Why Doing the Right Thing Helps Us Do the Best Science

Abstract Full Text
JAMA Oncol. 2023;9(10):1379-1380. doi:10.1001/jamaoncol.2023.2699
Cancer Care Chronicles

When Breasts Become a Liability—Discussing Risk-Reducing Mastectomy With Individuals Following Chest Irradiation for Childhood Cancer

Abstract Full Text
JAMA Oncol. 2023;9(10):1337-1338. doi:10.1001/jamaoncol.2023.2303

This essay describes a woman who had received chest irradiation for childhood cancer and the considerations for and against breast cancer risk–reducing mastectomy.

The Most Difficult Lesson From Cancer Just Might Be Its Most Valuable

Abstract Full Text
JAMA Oncol. 2023;9(10):1339-1340. doi:10.1001/jamaoncol.2023.2674

In this essay, the author reflects on his experience treating patients with cancer.

Poetry and Oncology

Cycles

Abstract Full Text
JAMA Oncol. 2023;9(10):1467. doi:10.1001/jamaoncol.2023.2777
Comment & Response

Validity of Meta-Analytical Data on Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors

Abstract Full Text
JAMA Oncol. 2023;9(10):1462. doi:10.1001/jamaoncol.2023.3384

Validity of Meta-Analytical Data on Cutaneous Adverse Events with Phosphoinositide 3-Kinase Inhibitors—Reply

Abstract Full Text
JAMA Oncol. 2023;9(10):1462-1463. doi:10.1001/jamaoncol.2023.3387

In Defense of Neuroendocrine Tumor Trials

Abstract Full Text
JAMA Oncol. 2023;9(10):1463-1464. doi:10.1001/jamaoncol.2023.3392

In Defense of Neuroendocrine Tumor Trials—Reply

Abstract Full Text
JAMA Oncol. 2023;9(10):1464-1465. doi:10.1001/jamaoncol.2023.3395

Coding Error in Study Evaluating Eligibility of US Black Women Under USPSTF Lung Cancer Screening Guidelines

Abstract Full Text
JAMA Oncol. 2023;9(10):1465. doi:10.1001/jamaoncol.2023.3505
Correction

Pervasive Data Errors in Abstract, Results, Figure 3, and Table 2

Abstract Full Text
free access
JAMA Oncol. 2023;9(10):1465. doi:10.1001/jamaoncol.2023.3537

Coding Errors in Study of Eligibility for Lung Cancer Screening

Abstract Full Text
free access
JAMA Oncol. 2023;9(10):1465. doi:10.1001/jamaoncol.2023.3792
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2023;9(10):1321. doi:10.1001/jamaoncol.2022.4876
×